Weight Loss & MetabolicGrade B
Retatrutide
A triple GLP-1/GIP/glucagon receptor agonist in late-stage trials, with the highest reported weight reduction to date in obesity studies.
- Regulatory status
- Investigational (Phase 3)
- Half-life
- ~6 days
- Route
- Subcutaneous, once weekly (trial protocols)
- Evidence
- Limited human trials or approved outside the US
Mechanism of action
Adds glucagon receptor agonism to dual incretin activity, increasing energy expenditure and hepatic fat mobilization alongside appetite suppression.
Studied and reported uses
- Investigational obesity therapy
- Investigational MASLD/MASH
Dosing information
Trial range1–12 mg weekly
StatusNo approved clinical dosing
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Side effects
- Nausea
- Vomiting
- Increased heart rate
- Dysesthesia signal reported
Research evidence
Phase 2
24.2% mean weight loss at 48 weeks on 12 mg.
Phase 3 program
TRIUMPH trials ongoing across obesity and T2D.